Profile data is unavailable for this security.
About the company
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is its nafamostat formulation for direct intravenous (IV) infusion being explored as an investigational product for the antiviral treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. Its pre-filled syringe product candidates include Fedsyra and Phenylephrine.
- Revenue in USD (TTM)398.00k
- Net income in USD-13.70m
- Incorporated2005
- Employees15.00
- LocationTalphera Inc1850 Gateway Drive, Suite 175SAN MATEO 94404United StatesUSA
- Phone+1 (650) 216-3500
- Fax+1 (302) 636-5454
- Websitehttps://talphera.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bon Natural Life Ltd | 25.56m | 2.47m | 7.03m | 96.00 | 0.6752 | 0.0682 | 1.87 | 0.275 | 2.62 | 2.62 | 22.95 | 25.95 | 0.5254 | 11.40 | 2.94 | 266,207.70 | 4.95 | 14.04 | 6.59 | 20.68 | 27.75 | 30.00 | 9.42 | 17.62 | 2.32 | 16.88 | 0.1438 | 0.00 | -1.29 | 22.32 | -26.32 | 83.09 | -6.70 | -- |
| Integrated BioPharma, Inc. | 50.32m | 112.00k | 7.10m | 147.00 | 89.39 | 0.3692 | 16.04 | 0.1412 | 0.0026 | 0.0026 | 1.62 | 0.6391 | 1.95 | 4.32 | 10.96 | 342,292.50 | 0.4338 | 13.15 | 0.5505 | 19.97 | 7.72 | 11.22 | 0.2226 | 5.87 | 1.08 | -- | 0.0004 | -- | -0.7006 | 0.1357 | 806.25 | -41.77 | 5.96 | -- |
| Lotus Pharmaceuticals Inc | 70.79m | 1.72m | 7.81m | 233.00 | 0.0524 | 0.0008 | 2.03 | 0.1104 | 0.0553 | 0.0553 | 2.56 | 3.58 | 0.6321 | 37.27 | 17.85 | 303,836.90 | 1.55 | 22.84 | 1.71 | 26.40 | 35.10 | 41.62 | 2.45 | 19.93 | 0.4428 | 30.80 | 0.0516 | 0.00 | 28.71 | 31.70 | -12.22 | 51.11 | 70.48 | -- |
| CV Sciences Inc | 15.85m | -2.53m | 8.50m | 42.00 | -- | 3.39 | -- | 0.5366 | -0.0157 | -0.0157 | 0.098 | 0.0139 | 1.69 | 1.55 | 25.35 | 377,285.70 | -26.94 | -43.42 | -73.44 | -77.75 | 46.06 | 51.81 | -15.95 | -45.68 | 0.2530 | -- | 0.0114 | -- | -1.24 | -19.80 | 133.96 | -20.87 | -- | -- |
| Aptorum Group Ltd | 431.38k | -2.82m | 9.68m | 3.00 | -- | 0.3691 | -- | 22.45 | -0.9126 | -0.9126 | 0.0954 | 4.80 | 0.0208 | 30.36 | 3.88 | 143,793.30 | -20.92 | -40.45 | -19.62 | -42.36 | 2.45 | -4.04 | -1,006.30 | -1,233.68 | 1.18 | -- | 0.1694 | -- | -66.71 | 2.38 | 71.18 | -- | -78.15 | -- |
| Bright Green Corp | 0.00 | -9.92m | 9.79m | 5.00 | -- | 0.993 | -- | -- | -0.0538 | -0.0538 | 0.00 | 0.0519 | 0.00 | -- | -- | 0.00 | -47.48 | -- | -72.55 | -- | -- | -- | -- | -- | -- | -- | 0.0494 | -- | -- | -- | 52.54 | -- | -- | -- |
| Healthy Extracts Inc | 2.88m | -1.37m | 10.72m | -- | -- | 26.79 | -- | 3.72 | -0.4725 | -0.4725 | 0.9845 | 0.1336 | 1.12 | 0.6654 | 28.03 | -- | -53.40 | -53.78 | -168.81 | -146.65 | 67.83 | 45.68 | -47.73 | -87.53 | 0.2059 | -0.9153 | 0.7131 | -- | 10.41 | 105.93 | -151.54 | -- | -- | -- |
| NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 11.84m | 1.00 | -- | 0.0661 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
| Talphera Inc | 398.00k | -13.70m | 13.42m | 15.00 | -- | 1.05 | -- | 33.73 | -0.6353 | -0.6323 | 0.0185 | 0.7491 | 0.0187 | -- | -- | 26,533.33 | -64.37 | -22.60 | -78.11 | -28.55 | -- | -- | -3,443.22 | -714.87 | -- | -- | 0.00 | -- | -- | -21.26 | -119.16 | -- | -34.33 | -- |
| Aytu Biopharma Inc | 81.00m | -15.84m | 14.39m | 99.00 | -- | 0.5043 | -- | 0.1776 | -2.86 | -2.86 | 14.63 | 4.64 | 0.6364 | 2.15 | 3.08 | 818,202.00 | -12.45 | -27.76 | -25.70 | -46.03 | 67.39 | 58.88 | -19.56 | -56.45 | 0.7916 | -0.0594 | 0.3531 | -- | -24.58 | 61.73 | 7.08 | -- | -- | -- |
| Cara Therapeutics Inc | 11.00m | -111.08m | 14.60m | 55.00 | -- | 1.26 | -- | 1.33 | -2.04 | -2.04 | 0.2017 | 0.2115 | 0.1063 | 1.10 | 2.10 | 199,927.30 | -107.38 | -35.76 | -132.61 | -40.82 | 74.66 | -- | -1,010.20 | -162.10 | 4.48 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
| Nexgel Inc | 5.01m | -3.39m | 16.92m | 19.00 | -- | 3.79 | -- | 3.38 | -0.5722 | -0.5722 | 0.8464 | 0.6589 | 0.4942 | 3.03 | 6.44 | 263,631.60 | -35.74 | -44.61 | -48.15 | -56.19 | 23.74 | 5.02 | -72.33 | -180.98 | 0.8135 | -- | 0.1992 | -- | 99.66 | 13.06 | 33.48 | -- | -- | -- |
| Cumberland Pharmaceuticals, Inc. | 37.79m | -10.38m | 17.76m | 91.00 | -- | 0.6735 | -- | 0.47 | -0.7328 | -0.7328 | 2.67 | 1.87 | 0.4501 | 0.8643 | 3.17 | 415,225.80 | -12.35 | -7.03 | -17.75 | -9.52 | 82.58 | 79.95 | -27.45 | -17.64 | 1.26 | -38.85 | 0.382 | -- | -5.85 | 6.15 | -12.73 | -- | -36.17 | -- |
| TherapeuticsMD Inc | 996.00k | -4.83m | 19.14m | 1.00 | -- | 0.6918 | -- | 19.22 | -0.4348 | -0.5538 | 0.0889 | 2.40 | 0.0212 | -- | 0.5048 | 996,000.00 | -10.31 | -53.35 | -13.13 | -111.61 | 45.08 | 86.67 | -485.34 | -236.57 | -- | -- | 0.00 | -- | -98.14 | -39.53 | -816.85 | -- | -- | -- |
Data as of Oct 08 2024. Currency figures normalised to Talphera Inc's reporting currency: US Dollar USD
25.22%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nantahala Capital Management LLCas of 31 Mar 2024 | 1.99m | 11.73% |
| Rosalind Advisors, Inc.as of 30 Jun 2024 | 758.97k | 4.47% |
| MAI Capital Management LLCas of 31 Mar 2024 | 469.58k | 2.76% |
| Rock Springs Capital Management LPas of 31 Mar 2024 | 316.46k | 1.86% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 177.29k | 1.04% |
| RBC Capital Markets LLC (Investment Management)as of 31 Mar 2024 | 151.16k | 0.89% |
| Geode Capital Management LLCas of 30 Jun 2024 | 143.13k | 0.84% |
| Values First Advisors, Inc.as of 30 Jun 2024 | 113.18k | 0.67% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 91.55k | 0.54% |
| Turtle Creek Wealth Advisors LLCas of 30 Jun 2024 | 71.50k | 0.42% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
